Voyager Therapeutics is a clinical-stage gene therapy company focused on developing treatments for patients suffering from severe diseases of the central nervous system. The Company focuses on CNS diseases where an adeno-associated virus, or AAV, gene therapy approach can have a clinically meaningful impact by either increasing or decreasing the production of a specific protein. Voyager has created a product engine that enables the Company to engineer, optimize, manufacture and deliver AAV-based therapies. AAV gene therapies have the potential to provide durable efficacy following a single administration directly to the CNS. The Voyager product engine has rapidly generated programs for six CNS indications, including advanced Parkinson’s disease, monogenic amyotrophic lateral sclerosis, Friedreich’s ataxia, Huntington’s disease, FTD / Alzheimer’s disease and chronic pain.